HIV Prevention Now Act
- Bill Number
- H.R. 5126
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-04: Referred to the House Committee on Appropriations.
- Last Updated
- 2026-01-08T09:06:56Z
AI-Generated Summary
Purpose
The "HIV Prevention Now Act" (H.R. 5126) aims to provide dedicated federal funding to support programs and activities focused on preventing and controlling HIV, viral hepatitis, sexually transmitted diseases (STDs), and tuberculosis. This funding targets the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention within the Centers for Disease Control and Prevention (CDC), a key public health agency.
Key Provisions
- Appropriation Amount: Allocates $2,165,000,000 specifically for fiscal year 2026 to the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention at the CDC.
- Treatment of Funds:
- The funds are in addition to any existing appropriations for the Department of Health and Human Services (HHS), which oversees the CDC.
- They must be used exclusively for the center's programs and activities related to preventing and addressing HIV, viral hepatitis, STDs, and tuberculosis.
- The funds cannot be transferred to any other entity outside this specific CDC center.
Significant Changes to Existing Law
This bill introduces new, targeted funding that supplements—rather than replaces—current appropriations for HHS and the CDC. It does not amend prior laws but establishes a dedicated funding stream to bolster prevention efforts, potentially increasing the overall budget for these public health initiatives without reallocating existing resources.
Potential Impacts
- On Government Agencies: Enhances the CDC's capacity to expand prevention programs, research, surveillance, and outreach, allowing for more robust responses to these diseases without straining other HHS budgets.
- On Citizens: Improves access to prevention services, testing, treatment, and education, particularly benefiting communities disproportionately affected by HIV, viral hepatitis, STDs, and tuberculosis, such as low-income groups, racial minorities, and high-risk populations. This could lead to reduced disease transmission and better public health outcomes.
- On International Relations: Minimal direct impact, though strengthened domestic prevention efforts may indirectly support global health initiatives led by the CDC, such as international disease surveillance and collaboration on pandemics.
Main Stakeholders Affected
- Government Entities: The CDC's National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention (primary recipient); broader HHS; and congressional appropriations committees overseeing federal health spending.
- Citizens and Communities: Individuals at risk for or living with HIV, viral hepatitis, STDs, or tuberculosis; healthcare providers, clinics, and nonprofits delivering prevention services; and underserved populations, including LGBTQ+ communities, people who inject drugs, and racial/ethnic minorities.
- Other Groups: Public health advocates, researchers, and state/local health departments that partner with the CDC on these programs.
Notable Legal, Constitutional, or Political Implications
- Legal: The bill uses Congress's constitutional power to appropriate funds (Article I, Section 9), ensuring targeted spending without violating separation of powers. Its restrictions on fund transfers promote accountability in federal budgeting.
- Constitutional: Aligns with the federal government's role in promoting general welfare (Preamble and Article I, Section 8), supporting public health as a national priority without infringing on state authority over health matters.
- Political: Represents bipartisan or multipartisan support (introduced by a diverse group of House members) for addressing ongoing public health crises, potentially influencing future appropriations debates on infectious disease funding amid competing budget priorities. It underscores a policy focus on prevention over reaction in epidemic control.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (33)
Rep. Garcia, Robert [D-CA-42], Rep. Nadler, Jerrold [D-NY-12], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Thompson, Bennie G. [D-MS-2], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. Garcia, Sylvia R. [D-TX-29], Rep. Velázquez, Nydia M. [D-NY-7], Rep. Sewell, Terri A. [D-AL-7], Rep. Carson, André [D-IN-7], Rep. Jackson, Jonathan L. [D-IL-1], Rep. Titus, Dina [D-NV-1], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. McIver, LaMonica [D-NJ-10], Rep. Beatty, Joyce [D-OH-3], Rep. Cleaver, Emanuel [D-MO-5], Rep. Cohen, Steve [D-TN-9], Rep. Wilson, Frederica S. [D-FL-24], Rep. Simon, Lateefah [D-CA-12], Rep. Thanedar, Shri [D-MI-13], Rep. Mullin, Kevin [D-CA-15], Rep. Ramirez, Delia C. [D-IL-3], Rep. Barragán, Nanette Diaz [D-CA-44], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Tlaib, Rashida [D-MI-12], Rep. Clarke, Yvette D. [D-NY-9], Rep. Williams, Nikema [D-GA-5], Rep. Latimer, George [D-NY-16], Rep. Moore, Gwen [D-WI-4], Rep. Figures, Shomari [D-AL-2], Rep. Ross, Deborah K. [D-NC-2], Rep. Lieu, Ted [D-CA-36], Rep. Pocan, Mark [D-WI-2], Rep. Johnson, Julie [D-TX-32]
Recent Actions
- 2025-09-04: Referred to the House Committee on Appropriations.
- 2025-09-04: Introduced in House
- 2025-09-04: Introduced in House
Bill Versions
- HIV Prevention Now Act — issued 2025-09-04 — PDF (2 pages)